Thymosin Alpha-1 Boosts Immune Killer Cells and T Cell Diversity in COVID-19 Patients

Peripheral blood mononuclear cells from 33 symptomatic COVID-19 patients (with and without Tα1 treatment) and 11 healthy controls (with and without Tα1) were analyzed using single-cell RNA sequencing (scRNA-seq) and T cell receptor sequencing (TCR-seq). Differential expression analysis and functional enrichment analysis were performed to identify immune changes mediated by Tα1.

This is one of the most detailed studies of how thymosin alpha-1 modifies the immune system, using advanced single-cell technology to reveal changes at individual cell level. The finding that Tα1 enhances NKT killer cells and diversifies T cell receptors provides a molecular rationale for its use as an immunomodulator — not just in COVID-19 but potentially in other infections and in immunocompromised patients.

Thymosin alpha-1 has been used clinically in over 30 countries, primarily for hepatitis B and as an immune adjuvant. Its use during the COVID-19 pandemic brought renewed attention to peptide-based immunomodulation. This single-cell study provides the deepest mechanistic evidence yet for how Tα1 reshapes the immune landscape, potentially informing its use in future pandemics and in immunodeficiency states.

The sample size is small (44 total participants), limiting statistical power. The study is observational without randomization — patients who received Tα1 may have differed from those who didn't. The scRNA-seq analysis captures a snapshot at one time point, not the dynamic immune response over time. Clinical outcomes (symptom improvement, hospital stay, mortality) were not correlated with the immunological findings. The COVID-19 variants involved were not specified.